You are here

RNAi

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Pharmaceutical Business Review

Flag link:

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Fierce Biotech

Flag link:

RNAi company Dicerna raises $100M follow-on

RNAi company Dicerna raises $100M follow-on

BioCentury

Dicerna Pharmaceuticals

Flag link:

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

Xconomy

Flag link:

Sirnaomics cleared to start first trial of RNAi lead in cancer

Sirnaomics cleared to start first trial of RNAi lead in cancer

Fierce Biotech

Flag link:

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

Motley Fool

Flag link:

After Alnylam’s solo maiden launch, here comes the tricky bit

After Alnylam’s solo maiden launch, here comes the tricky bit

EP Vantage

Flag link:

In first, FDA approves RNA interference drug from Alnylam

In first, FDA approves RNA interference drug from Alnylam

Biopharma Dive

hATTR amyloidosis

Flag link:

With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree

Fierce Pharma

Flag link:

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Endpoints

Axovant Sciences

Flag link:

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

Endpoints

Alzheimer's disease

Flag link:

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Yahoo/Zacks.com

hereditary ATTR amyloidosis

Flag link:

Alnylam outshines Ionis with RNAi drug

Alnylam outshines Ionis with RNAi drug

BioPharma Dive

Ionis Pharmaceuticals

Flag link:

Dicerna and Boehringer partner on RNAi treatment for NASH

Dicerna and Boehringer partner on RNAi treatment for NASH

Endpoints

Boehringer Ingelheim

Flag link:

A drug 15 years in the making: Alnylam's quest to prove RNAi

A drug 15 years in the making: Alnylam's quest to prove RNAi

BioPharma Dive

Flag link:

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Stat

familial amyloid polyneuropathy

Flag link:

Alnylam review turns up no clear answers on revusiran deaths

Alnylam review turns up no clear answers on revusiran deaths

BioPharma Dive

Flag link:

EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts

EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts

Fierce Biotech

artificial intelligence

Silence Therapeutics

Flag link:

Alnylam lines up Phase 3 for another RNAi drug

Alnylam lines up Phase 3 for another RNAi drug

BioPharma Dive

acute hepatic porphyrias

Flag link:

Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug

Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug

Endpoints

clinical trials

Flag link:

Pages